Latest Breaking News On - Principal investigator for the company - Page 1 : comparemela.com

Positive results in Phase 3 open label study of fasedienol (PH94B) in social anxiety disorder (SAD) Positive U.S. Food and Drug Administration (FDA) feedback on the use of the Liebowitz Social Anxiety Scale (LSAS) as the primary efficacy endpoint in future Phase 3 studies of fasedienol in SAD Successful itruvone (PH10) U.S. Phase 1 study supports previous successful Phase 1 studies and a positive Phase 2A study in major depressive disorder (MDD) conducted outside the U.S. and facilitates next-step U.S. Phase 2B development in MDD Clinical-stage pipeline expanded to six differentiated product candidates targeting multiple large CNS markets Pursuing multiple global and regional strategic development and commercialization partnerships to accelerate clinical and regulatory milestones across the CNS pipeline

Columbia universityNew yorkUnited statesNew york state psychiatric instituteShawn singhMichaelr liebowitzInternational number tollPrincipal investigator for the companyEuropean patent officeTrademark officeExchange commissionYork state psychiatric instituteResearch networkChief executive officerLiebowitz social anxiety scaleNew drug application